Cosibelimab not checked

Checkpoint Therapeutics, Inc. · TG-1501 · CK-301

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
None yet
 
Trials
1 active
4 in total · 1 in the EU
Targets
 

What this is

How it works
Releases a brake on the immune system (PD-1 or PD-L1) so it attacks cancer cells.Programmed Death Ligand-1 Blocker FDA class
Tested for
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Malignant Mesothelioma, Advanced, Head and Neck Cancer, Melanoma, Merkel Cell Carcinoma, Renal Cell Carcinoma and 5 more
Main trialPhase 1
“CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.”In the company’s words, NCT03212404 on ClinicalTrials.gov
Other names
TG-1501 · CK-301

Other drugs for Lung Neoplasms

All 676 drugs for Lung Neoplasms

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials4

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting 18 Nov 2021 Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Phase 3Terminated 30 Dec 2023 Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC
Phase 1Completed 4 Nov 2021 Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation
Phase 1Terminated 3 May 2022 Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Cosibelimab

Following is part of Solo: you see every change to Cosibelimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in